<DOC>
	<DOCNO>NCT02234310</DOCNO>
	<brief_summary>The primary objective study evaluate safety rFIXFc ( recombinant coagulation factor IX Fc fusion protein , BIIB029 ) previously untreated participant severe hemophilia B . Secondary objective evaluate efficacy rFIXFc prevention treatment bleed episode previously untreated participant ( PUPs ) , evaluate rFIXFc consumption prevention treatment bleed episode previously untreated participant .</brief_summary>
	<brief_title>Study Determine Safety Efficacy rFIXFc Untreated Males With Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Key Weight &gt; =3.5 kilogram time inform consent Severe hemophilia B define &lt; =2 IU/dl ( &lt; =2 % ) endogenous factor IX document medical record test Screening Period . Key Prior history inhibitor define report laboratory . Measurable inhibitor activity Screening Visit , measure use Nijmegenmodified Bethesda assay History hypersensitivity reaction associate intravenous immunoglobulin administration History hypersensitivity reaction associate recombinant coagulation factor IX Fc fusion protein ( rFIXFc ) administration Other coagulation disorder addition hemophilia B Injection FIX concentrate rFIXFc More 3 injection rFIXFc prior confirmation eligibility NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prophylaxis treatment</keyword>
	<keyword>episodic treatment</keyword>
</DOC>